R. Hutchings

Comparison Of Disease Status And Outcomes Of Patients With Psoriatic Arthritis (Psa) Receiving Their First Biologic In Uk, Germany, France, Italy And Spain (5eu)

(range:15.1mm/h (France)-21.0mm/h (Italy)) and CRP (range:5.6mg/dl (Spain)12.5mg/dl (UK)). Current disease severity per physician-judgment (mild:moderate:severe) in 5EU were: UK-68%:22%:10%, Germany-57%:39%:5%, France-46%:47%:7%, Italy-64%:34%:2%, Spain-69%:27%:4%. Among patients with available data, current HAQ (range: 0.7(France)-1.5(Germany)), BASDAI (range:3.0(Spain)-3.4(UK)), 100mmVAS (range:19.0(France)-31.4(UK)) and Swollen Joint Count (range:0.5(France)-(3.7(UK)) differed within 5EU. Among patients with available data, response to current biologic per ASAS criteria were (%ASAS20:%ASAS40:ASAS5/6:%ASAS partial-remission): UK-12%:6%:0%:4%, Germany-20%:9%:9%:11%, France-13%:7%:7%:11%, Italy-30%:17%:13%:18%, Spain19%:13%:5%:13%. CONCLUSIONS: Among AS patients receiving their first biologic, disease severity differed within 5EU, with patients in the UK with relatively higher burden and poorer treatment response. Impact of specific biologic treatments on the observed patterns warrants further scrutiny.